Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareSource Drug List Coverage & Prior Auth Update …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCareSourcePolicy 00026141

    List of Covered Drugs (Drug List) — CareSource MyCare Ohio

    Customize your policy alerts

    Sign up for CareSource Policy 00026141 alerts

    Get alerted when Policy 00026141 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    CareSource MyCare Ohio formulary describing covered drugs, utilization controls (prior authorization, quantity limits, step therapy), and member/provider processes for exceptions and temporary supplies.

    Policy Summary
    PayerCareSource
    PolicyList of Covered Drugs (Drug List) — CareSource MyCare Ohio
    Policy CodePolicy 00026141
    Change TypeAdministrative update — drug list refresh (no material clinical changes)
    Effective Date05/01/2026
    Last ReviewAug 31, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization when 'PA' is listed for a drug to avoid claim denial; contact Member Services for exception submission.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    V10formulary version
    05/01/2026document update
    1-855-475-3163member services
    30 daysadvance notice
    30-daytemporary supply (new members)
    04/14/2026drug list last updated

    Coverage Criteria and General Rules

    General coverage conditions

    Covered when ALL of the following are met

    Standard coverage conditions: Prescriber states the drug is medically necessary for the member

    From Drug List coverage rules

    Payer medical necessity agreement: CareSource MyCare Ohio agrees the drug is medically necessary for the member

    From Drug List coverage rules

    Network pharmacy dispensing: Prescription is filled at a CareSource MyCare Ohio network pharmacy

    From Drug List coverage rules

    Temporary and transition coverage

    Temporary/transition supplies covered in specific scenarios

    Policy Summary
    PayerCareSource
    PolicyList of Covered Drugs (Drug List) — CareSource MyCare Ohio
    Policy CodePolicy 00026141
    Change TypeAdministrative update — drug list refresh (no material clinical changes)
    Effective Date05/01/2026
    Last ReviewAug 31, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization when 'PA' is listed for a drug to avoid claim denial; contact Member Services for exception submission.
    SourceLink
    On This Page
    Coverage Criteria and General RulesProvider Responsibilities, Prior Authorization, and DocumentationFormulary Codes, Requirement Flags, and Quantity Limit ExamplesStep Therapy Rules and IndicatorsQuantity Limits (Examples and Per-Drug Values)Site-of-Care Notes and Infusion RequirementsDefinitions and AbbreviationsBackground and Document PurposeBiosimilar and Biological Product Substitution
    New member temporary supply: Plan may cover a temporary 30-day supply during the first 90 days of membership when the drug is not on the Drug List, plan rules limit the amount ordered, the drug requires prior authorization, or the drug is subject to step therapy30 days

    From B9

    One-time supply for unplanned transitions: In the event of an unplanned transition or level-of-care change, the plan may cover a one-time temporary supply up to 31 days31 days

    From B9

    Long-term care immediate supply: For members in a nursing home or long-term care facility who need a drug not on the Drug List, the plan will cover one 31-day supply (unless prescription is written for fewer days)31 days

    From B9

    Temporary Supply Coverage

    Temporary supply coverage rules

    Temporary supplies for new members or transitions: Cover temporary supply up to 30 days for new members within first 90 days if drug not on Drug List, plan rules limit amount, drug requires prior authorization, or drug is part of step therapy; allow multiple refills to provide up to 30 days if prescription written for fewer days30-day

    From B9

    Long-term care / unplanned transition temporary supply: If member has been in the plan >90 days and lives in long-term care facility or an unplanned transition occurs, cover one 31-day supply unless prescription specifies fewer days31-day

    From B9

    Exception Process and Timelines

    Exception request and decision timelines

    Exception submission: Member or prescriber may request an exception to cover a drug not on the Drug List or to change plan rules (for example, quantity limits, step therapy, or prior authorization); Member Services will assist with submitting the request

    From B10 and B11

    Decision timelines: Standard exception decision within 72 hours after receiving the prescriber's supporting statement; expedited exception decision within 24 hours if waiting may seriously harm the member; prescriber's supporting statement should be faxed to 1-877-328-966072 hours / 24 hours

    From B12

    Formulary Structure and Coverage

    Formulary coverage and tiers

    Copays and tiers: Members have no copays for Part D covered prescription and OTC drugs when following the plan's rules; drugs are grouped into tiers (Tier 1–5) with tiers reflecting generic/brand distinctions

    From B19

    Formulary rules and symbols: The List of Covered Drugs uses requirement/limit symbols such as PA (Prior Authorization), QL (Quantity Limit), ST (Step Therapy), MO (Mail-Order), NDS (Non-Extended Days), and B/D PA (may be covered under Part B or D); these symbols indicate the actions or restrictions that apply to each drug

    From C1

    Coverage conditioned on listed requirements

    Coverage and utilization management for listed drugs are governed by the Requirements/Limits column; coverage is conditional on meeting those controls

    Formulary controls: Drug coverage depends on meeting Requirements/Limits entries such as PA (prior authorization), B/D PA (Part B/Part D determination), MO (mail-order/management indicator), LA (limited availability), ST (step therapy), NDS (non-extended days), and QL (quantity limit); failure to meet these requirements may result in noncoverage or denial

    From formulary 'Requirements / Limits' definitions and antineoplastic/immunosuppressant entries

    Drugs that are removed from the market or determined to be unsafe may be taken off the CareSource MyCare Ohio Drug List immediately and will not be covered.

    When a formulary entry lists PA (Prior Authorization), the plan requires approval before the prescription can be filled; if prior authorization is not obtained, CareSource MyCare Ohio may not cover the drug.

    Within the excerpted formulary segments provided here there are no standalone explicit exclusion statements; the drug listings instead use requirement and limits codes (e.g., PA, QL, MO, NDS, LA, B/D) and refer readers to the table legend at the start of the full Drug List for symbol meanings that may imply coverage constraints.

    The partial drug table shown in this excerpt does not include explicit exclusion conditions for specific products; coverage language is conveyed via the Requirements/Limits column entries rather than separate exclusion statements in these chunks.

    This segment of the Drug List does not list explicit exclusions; instead, the table uses symbols and abbreviations in the Requirements/Limits column. Users should consult the formulary legend at the beginning of the full table to interpret symbol meanings that drive coverage decisions.

    The provided extract includes many requirement flags (e.g., PA, MO, QL, NDS, LA, B/D) and quantity limits but does not contain standalone exclusion language; coverage conditions for each line are determined by the Requirements/Limits entries and the table legend.

    CareSource MyCare Ohio will cover drugs listed on the Drug List when the prescriber determines the drug is medically necessary, CareSource MyCare Ohio agrees the drug is medically necessary, and the prescription is filled at a CareSource MyCare Ohio network pharmacy.

    No explicit 'Not Medically Necessary' (NMN) statements appear in the excerpted sections; coverage determinations in this extract are expressed through the Drug List entries and the Requirements/Limits codes rather than by separate NMN declarations.

    This partial section does not include explicit statements labeling drugs as 'Not Medically Necessary.' Instead, access is controlled through the Requirements/Limits codes (e.g., PA, MO, QL, NDS) applied to individual formulary entries.

    Within the provided excerpt there are no line‑level declarations that a drug is 'not medically necessary.' The plan communicates coverage conditions via the Drug List and the associated requirement/limit codes; for full NMN determinations refer to the complete policy and PA criteria.

    Provider Responsibilities, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization required — Some drugs listed on this Drug List require prior authorization (PA) from CareSource MyCare Ohio before the prescription can be filled. If prior authorization is not obtained when required, the Plan may not cover the drug and the claim may be denied.

    • PA = Prior Authorization — approval required before dispensing
    • Many antineoplastic and immunosuppressant drugs and select high-tier or specialty products frequently require PA or B/D PA (benefit/setting determination) as shown in the Requirements/Limits column
    Documentation Required

    Prior authorization and requirement codes

    Prior authorization and requirement codes — The formulary uses requirement codes in the 'Requirements/Limits' column that may affect coverage. These include PA (Prior Authorization), B/D PA (may be covered under Medicare Part B or D depending on use/setting), MO (Mail-Order availability), LA (Limited Availability), QL (Quantity Limit), NDS (Non‑Extended Days' Supply), and ST (Step Therapy). Failure to meet the indicated requirement(s) may result in denial or reduced coverage.

    • B/D PA: may require documentation to determine Part B vs Part D coverage
    • MO: mail-order designation — may be required or preferred for maintenance meds
    • LA: limited to certain pharmacies; call Customer Service for details
    • QL and NDS: quantity and days' supply limits applied as indicated
    • ST: step therapy — prescriber must try required agent(s) first
    Prior Authorization

    Prior authorization required for many listed drugs

    Prior authorization required for many listed drugs — Numerous drugs across therapeutic categories (including many antineoplastic and immunosuppressant agents, specialty drugs, and certain formulations) list PA, B/D PA, or other requirement codes in the Requirements/Limits column. Examples include oral, IV, and injectable formulations where PA and site/setting documentation is commonly required.

    • Many entries include PA or B/D PA and may also carry MO, LA, QL, NDS, or ST flags
    • Site-of-care or formulation-specific PA may apply (e.g., certain IV or infusion products)
    Documentation Required

    Prior authorization and requirement summary

    Prior authorization and requirement summary — To receive coverage, providers must follow the Requirements/Limits for each formulary entry. Requirements may include submitting clinical documentation, fulfilling step therapy, adhering to quantity limits, or confirming the benefit/setting. Requests that require B/D PA need supporting documentation describing use and setting to determine Part B vs Part D coverage.

    • Follow the exact codes shown in the 'Requirements/Limits' column for each drug
    • B/D PA entries generally require additional clinical documentation to determine coverage pathway
    Prior Authorization

    PA required for specific formulations

    PA required for specific formulations — Some formulations (for example, certain intravenous, injectable, or high-cost specialty formulations) specifically include 'PA' or 'B/D PA' in their Requirements/Limits. Check the formulation-level line in the table for PA, MO, LA, QL, or NDS flags before dispensing.

    • Formulation-specific entries may carry different requirements than other formulations of the same active ingredient
    • If Requirements/Limits lists PA for a given formulation, obtain PA prior to dispensing
    Denial Risk

    Prior authorization required where noted

    Prior authorization required where noted — Certain products and dose forms list 'PA' in the Requirements/Limits (for example, many oncology, infusion, and specialty products). Claims for these items may be denied if PA or B/D PA (when applicable) is not obtained.

    • Examples across therapeutic classes — review the Requirements/Limits column on the drug line
    • Denial is possible if PA or B/D PA is not in place
    Denial Risk

    Prior Authorization Denial Risk

    Prior Authorization Denial Risk — Failure to obtain required prior authorization, to satisfy step therapy (ST), to comply with quantity limits (QL/NDS), or to submit required B/D PA documentation may result in claim denial or noncoverage.

    • PA, B/D PA, ST, MO, LA, QL, and NDS are actionable requirements — not meeting them can trigger denial
    • For B/D PA, lack of setting/use documentation may prevent correct Part B vs Part D adjudication
    Denial Risk

    Requirement codes may trigger denial or restriction

    Requirement codes may trigger denial or restriction — The codes shown in the Requirements/Limits column indicate utilization management controls that must be satisfied for coverage. Examples include PA (prior authorization), ST (step therapy), QL (quantity limits), NDS (non‑extended days' supply), MO (mail-order), LA (limited availability), and B/D PA (benefit/setting review).

    • Claims not meeting the listed Requirements/Limits may be denied or require additional follow-up
    • Consult the specific drug line to determine which controls apply
    Note

    Member document access and Exception Supporting Statement

    Member document access and exception support — Members may request this Drug List or other plan documents in alternate formats (large print, braille, audio) or other languages by calling Member Services. For exception requests that need prescriber supporting statements, fax the prescriber's statement to the number provided.

    • Member Services: 1-855-475-3163 (TTY: 1-833-711-4711 or 711), Mon–Fri 8 a.m.–8 p.m. ET (extended availability Oct 1–Mar 31)
    • Exception prescriber supporting statement fax: 1-877-328-9660 — standard decision within 72 hours; expedited within 24 hours if prescriber certifies harm from delay
    Documentation Required

    Definitions and support contact; Submission guidance

    Definitions, provider support contact, and submission guidance — The formulary defines the codes and abbreviations at the start of the drug table. Providers should consult that legend and follow the Requirements/Limits when submitting authorization requests. Documentation requirements vary by requirement code (B/D PA often requires setting/use documentation; PA may require clinical justification).

    • Consult the formulary legend for meanings of PA, B/D PA, MO, LA, QL, NDS, ST
    • Submit required clinical documentation as specified for B/D PA or PA requests
    • For questions or to submit requests, call CareSource MyCare Ohio Provider Services at 1-855-475-3163 (TTY details as above)
    Step Therapy

    Step therapy / specialty requirements

    Step therapy and specialty requirements — Some drugs are subject to step therapy (ST) or other program-specific requirements. When ST applies, required prior agents must be tried and documented before the requested drug will be covered. Certain specialty products may carry LA, MO, or B/D PA flags reflecting benefit, site, or distribution controls.

    • ST indicates a required trial of specified agents before coverage of an alternative
    • Temporary 30‑day supply may be available for new members during transition (chunk 18)
    • LA and MO flags indicate limited pharmacy availability or mail‑order pathways for specialty agents

    Formulary Codes, Requirement Flags, and Quantity Limit Examples

    Selected Formulary Products (neutral)mixed
    AIMOVIGAIMOVIG AUTOINJECTOR — Requirements /Limits = PA; MO; QL (1 per 30 days).
    EMGALITYEMGALITY PEN / SUBCUTANEOUS SYRINGE 120 — Requirements /Limits = PA; MO; QL (2 per 30 days).
    XCOPRIXCOPRI TITRATION PACK / ORAL TABLETS — referenced as drug name for topiramate products; QL (28 per 180 days) for some formulations.
    VALTOCOVALTOCO — Requirements /Limits = PA; MO; QL (10 per 30 days).
    INBRIJAINBRIJA — referenced in antineoplastic/neurology lists (ensure present in formulary mapping).
    NEUPRONEUPRO — referenced in neurology / movement disorder product group; ensure availability and any QL or MO flags.
    Quantity Limit Examples (neutral)mixed
    QL_120_30Example: QL (120 per 30 days) — e.g., itraconazole, famciclovir, EVOTAZ/ETRAVIRINE entries.
    QL_28_28Example: QL (28 per 28 days) — e.g., some PAXLOVID/SOFOSBUVIR/VALTOCO related entries.
    QL_84_28Example: QL (84 per 28 days) — e.g., MAVYRET oral tablet.
    QL_4000_10Example: QL (4000 per 10 days) — vancomycin IV piggyback examples.
    QL_40_10Example: QL (40 per 10 days) — vancomycin oral capsule.
    QL_240_30Example: QL (240 per 30 days) — AUGTYRO.
    QL_66_28Example: QL (66 per 28 days) — AVMAPKI-FAKZYNJA.
    QL_30_30Example: QL (30 per 30 days) — many oncology oral products.
    QL_180_30Example: QL (180 per 30 days) — multiple antineoplastics (e.g., abiraterone).
    QL_60_30Example: QL (60 per 30 days) — various products.
    1–10 of 18
    1/2
    Requirement/Management Codes (neutral)mixed
    PAPrior Authorization required for listed products (PA).
    MOMail-Order availability flag (MO).
    LALimited Availability (LA) — specialty or limited pharmacies.
    NDSNon-Extended Days' Supply (NDS) — limited to 30-day supply at retail/mail-order.
    B/D PAMay require Part B vs Part D determination (B/D PA).

    Step Therapy Rules and Indicators

    RequirementSummary / Plan action
    Step therapy (ST)Members must try specified prior agent(s) before the plan will cover a next‑line drug; prescriber may document failure or contraindication to the prior agent to allow coverage of the alternative.
    Temporary supply during step reviewDrugs subject to step therapy may be eligible for a temporary 30‑day supply for new members while exception or transition requests are processed.
    Step Therapy IndicatorMeaning / Plan action
    ST (Step Therapy)Plan requires specified first‑line drugs to be tried for the medical condition before covering alternative drugs; if first drug fails or is not tolerated, second drug may be covered upon documentation.
    Table legend referenceSee the formulary table legend at the beginning for specific drug‑level step therapy details and required sequence; providers may call Member Services for clarification.
    Flags presentInterpretation
    PA; MO; LAEntries showing combinations such as PA; MO; LA indicate prior authorization and management/limited‑access routing may apply and can reflect step or specialty requirements; specific step algorithms are not provided in these excerpts.
    NDSNon‑drug‑specific (NDS) appears alongside other flags and may affect how step/management rules are applied per the formulary legend.
    Agent / Flag examplesImplication for step or authorization
    ADCETRIS; many antineoplastic agents (e.g., ALECENSA, azacitidine)Marked B/D PA; MO; NDS or PA; LA indicating layered authorization (benefit/diagnosis PA, medical override, limited access) — may require multiple authorization pathways before coverage.
    AUGTYRO; AYVAKIT; BALVERSAExamples show PA with LA or B/D PA flags — plan applies prior authorization and may route approvals through specialty/benefit review consistent with step/managed processes.
    FlagsPractical effect
    MO; LAMO (medical/management override) and LA (limited access) flags indicate utilization management or step‑edit controls may apply to the listed product; exact step criteria are defined in the full formulary legend or PA criteria.
    B/D PAB/D PA denotes benefit/diagnosis or billing/documentation prior authorization which may functionally operate like a step/managed edit for coverage determinations.
    DrugStep-like controls / Limits
    AIMOVIG (autoinjector)Requirements/Limits = PA; MO; QL (1 per 30 days) — prior authorization plus a quantity limit of 1 per 30 days restricts access and functions similarly to step management.
    Product / EntryStep Therapy note
    EXXUA (extended release formulations)Requirements/Limits include ST and QL (e.g., ST; QL (30 per 30 days)) indicating step therapy is required for specific formulations.
    FANAPT titration packsEntries list ST; MO; QL (varies) for FANAPT titration packs — step therapy applies to these formulations per the Requirements/Limits column.
    ProductST flag
    RALDESYRequirements/Limits = ST; MO; NDS — 'ST' present indicates step therapy applies to RALDESY per the formulary entry.
    General observationSupporting detail
    Step therapy not fully enumeratedThis segment does not provide full step therapy algorithms for most agents; several agents are listed with PA requirements indicating prior authorization is required before coverage.
    Flag examplesPossible meaning re: step edits
    B/D PABenefit/diagnosis or billing/documentation PA entries (B/D PA) may reflect step therapy or benefit‑based edits requiring additional review prior to coverage.
    Managed (MO) entriesMO combined with PA/QL flags indicates utilization management; when present these may function as step‑like edits though specific sequences are not shown here.
    Requirement / FlagOperational effect (provider action)
    PA (Prior Authorization)Many listed products require prior authorization before the prescription will be covered; failure to obtain PA may result in noncoverage — follow the Requirements/Limits field for each product and submit supporting documentation as required.
    QL (Quantity Limit) / NDC restrictionsAdhere to quantity limits (QL) shown per time period and any NDC‑specific restrictions noted (e.g., 'ONLY NDCS STARTING WITH ...'); claims exceeding QL or using non‑allowed NDCs may be denied or require override.
    ST / MO / LA / B/D PAStep therapy (ST) and management flags (MO, LA) and billing/benefit PA (B/D PA) indicate additional utilization management controls — providers should consult the formulary legend and submit PA or exception requests as applicable.

    Quantity Limits (Examples and Per-Drug Values)

    inv-135: plan may impose quantity limits — overview
    Plan policyPlan may impose quantity limits on drugs (see Requirements/Limits column)
    Provider contactCall CareSource MyCare Ohio at 1-855-475-3163 for questions
    Formulary legendSymbols/abbreviations are defined at the beginning of the full table
    inv-136: itraconazole oral capsule — 120
    Productitraconazole oral capsule
    Quantity limit (numeric)120
    Time periodper 30 days
    inv-137: Examples: PAXLOVID; valacyclovir; MAVYRET; fidaxomicin — varies by drug entry
    Example drugsPAXLOVID; valacyclovir; MAVYRET; fidaxomicin
    VariationQuantity limits vary by drug entry (examples shown in table)
    See entriesRefer to specific product lines for exact QL and time period
    inv-138: amikacin injection solution — (14 per 14 days)
    amikacin injection solution(14 per 14 days)
    Requirements notedPA; MO in formulary entry
    Formulary contextListed under miscellaneous antiinfectives
    inv-139: CAYSTON — QL (84 per 56 days)
    CAYSTONQL (84 per 56 days)
    RequirementsPA; MO; LA; NDS (per entry)
    Drug classPseudomonas antiinfective (formulary listing)
    inv-140: VANCOMYCIN IV PIGGYBACK — QL (4000 per 10 days)
    VANCOMYCIN IV PIGGYBACKQL (4000 per 10 days)
    Other limitsVariants show PA; MO; QL with differing numeric values per formulation
    ContextIV piggyback entries imply infusion setting
    inv-141: vancomycin oral capsule 125 mg — QL (40 per 10 days)
    Productvancomycin oral capsule 125 mg
    Quantity limitQL (40 per 10 days)
    RequirementsPA; MO; QL (per formulary)
    inv-142: abiraterone oral tablet 250 mg — QL (120 per 30 days)
    abiraterone oral tablet 250 mgQL (120 per 30 days)
    RequirementsPA; MO; QL (60 per 30 days shown for other strength entries)
    Therapeutic classAntineoplastic / immunosuppressant
    inv-143: AUGTYRO ORAL CAPSULE 40 MG — 240
    AUGTYRO ORAL CAPSULE 40 MG240 per 30 days
    TierTier 5 (per entry)
    RequirementsPA; QL (240 per 30 days); NDS
    inv-144: AVMAPKI- FAKZYNJA — 66
    AVMAPKI- FAKZYNJA66 per 28 days
    RequirementsPA; QL (66 per 28 days); NDS
    Formulary noteListed under antineoplastic agents
    inv-145: COMETRIQ ORAL CAPSULE 100 MG/DAY — 56
    COMETRIQ ORAL CAPSULE 100 MG/DAY56 per 28 days
    RequirementsPer formulary entry
    Therapeutic classAntineoplastic
    inv-146: ERLEADA ORAL TABLET 60 MG — 120
    ERLEADA ORAL TABLET 60 MG120 per 30 days
    RequirementsPA; MO; QL (per entry)
    Therapeutic areaOncology
    inv-147: FYARRO — 126
    FYARRO126 per 28 days
    RequirementsPA; QL (126 per 28 days); NDS
    MappingMapped to GOMEKLI entries in table
    inv-148: gemcitabine intravenous solution — 120
    gemcitabine intravenous solution120 per 30 days
    RequirementsPA; QL (120 per 30 days) for certain formulations
    NotesVarious strengths/formulations have differing QLs in table
    inv-149: GOMEKLI ORAL CAPSULE examples — 126 per 28 days; 84 per 28 days; 30 per 30 days
    GOMEKLI oral capsule examples126 per 28 days; 84 per 28 days; 30 per 30 days (varies by entry)
    RequirementsPA; QL per specific entry
    ContextMultiple line items show different QLs for GOMEKLI variants
    inv-150: gemcitabine various formulations — 90 per 30 days; 120 per 30 days; 21 per 28 days
    Gemcitabine formulationsExamples: 90 per 30 days; 120 per 30 days; 21 per 28 days (varies by formulation)
    RequirementsPA; MO; QL for specific formulations
    TieringEntries span tiers 2–5 depending on formulation
    inv-151: JAYPIRCA; KEYTRUDA; KISQALI — 30 per 30 days; 60 per 30 days; 28 per 28 days; 21 per 28 days
    JAYPIRCA / KEYTRUDA / KISQALI examples30 per 30 days; 60 per 30 days; 28 per 28 days; 21 per 28 days
    Requirement flagsPA; MO; QL present for many strengths
    TieringTypically Tier 5 for many strengths but varies
    inv-152: LUMAKRAS; LORBRENA; LUNSUMIO — 240 per 30 days; 90 per 30 days; 140 per 28 days
    LUMAKRAS / LORBRENA / LUNSUMIO240 per 30 days; 90 per 30 days; 140 per 28 days (examples)
    RequirementsPA; MO; QL as listed per strength
    NotesMultiple strengths show different QLs and tiers
    inv-153: octreotide micropheres IM suspension ER — QL (14 per 28 days)
    Octreotide microspheres IM ERQL (14 per 28 days)
    RequirementsPA; MO; QL; NDS on formulary
    Therapeutic areaAntineoplastic/immunosuppressant listings include this formulation
    inv-154: PEMAZYRE — QL (28 per 28 days)
    PEMAZYREQL (28 per 28 days)
    RequirementsPA; LA; QL; NDS (per entry)
    Drug mappingMapped to PRALATREXATE IV solution in table
    inv-155: TAFINLAR oral tablet — QL (840 per 28 days)
    TAFINLAR oral tablet for suspensionQL (840 per 28 days)
    RequirementsPA; MO; QL; NDS
    Therapeutic useAntineoplastic listing
    inv-156: VENCLEXTA tablets — examples include QL (60 per 30 days), QL (180 per 30 days), QL (30 per 30 days)
    VENCLEXTA (various strengths)Examples include QL (60 per 30 days); QL (180 per 30 days); QL (30 per 30 days)
    RequirementsPA; LA; QL; NDS depending on strength
    NotesStarting packs and strengths have distinct QL patterns
    inv-157: VENCLEXTA various strengths — QL examples: 60/30; 30/30; 180/30
    VENCLEXTA QL patternsQL examples: 60 per 30 days; 30 per 30 days; 180 per 30 days
    TieringTiers vary by strength (3 or 5)
    Requirement flagsPA; LA; NDS noted
    inv-158: VITRAKVI — QL examples: 60 per 30 days; 90 per 30 days; 180 per 30 days; 300 per 30 days
    VITRAKVIQL examples: 60 per 30 days; 90 per 30 days; 180 per 30 days; 300 per 30 days
    RequirementsPA; MO; LA; QL; NDS
    FormulationsCapsules and solutions with differing QLs
    inv-159: ZEJULA / ZELBORAF / other — QL examples: 30 per 30; 224 per 28; 600 per 30
    ZEJULA / ZELBORAF / otherQL examples: 30 per 30; 224 per 28; 600 per 30
    RequirementsPA; MO; LA; QL depending on strength
    NotesMultiple QL patterns appear across these agents in table
    inv-160: Antiepileptic agents — multiple QL entries including 60/30, 90/30, 120/30, 360/30, 480/30, 720/30, 2160/30, 1200/30
    Antiepileptic agents QLsMultiple QL entries including 60/30, 90/30, 120/30, 360/30, 480/30, 720/30, 2160/30, 1200/30
    gabapentin 600 mg180 per 30 days
    gabapentin 800 mg120 per 30 days
    inv-161: gabapentin 600 mg — 180
    gabapentin 600 mg (oral)180 per 30 days
    gabapentin 800 mg (oral)120 per 30 days
    Formulary flagsMO; QL (per entry)
    inv-162: gabapentin 800 mg — 120
    gabapentin 800 mg (oral)120 per 30 days
    RequirementsMO; QL (per formulary)
    ContextListed among antiepileptic entries
    inv-163: levetiracetam IV piggyback 1000/500 mg/100 ml — 30
    levetiracetam IV piggyback 1000/500 mg/100 ml30 per 30 days
    RequirementsMO; QL (per entry)
    MappingAssociated with oral levetiracetam entries
    inv-164: XCOPRI tablets — 30
    XCOPRI tablets (100 mg, 25 mg, 50 mg)30 per 30 days
    Maintenance packQL (56 per 28 days) for maintenance pack variant
    RequirementsMO; QL per entry
    inv-165: glatiramer 40 mg/ml example — 12
    glatiramer 40 mg/ml (example)12 per 28 days
    RequirementsPA; MO; QL (per entry)
    UseMultiple MS therapy entries reference this QL
    inv-166: dalfampridine — 60
    dalfampridine60 per 30 days
    RequirementsPA; MO; QL (per formulary)
    Therapeutic classNeurology agents
    inv-167: dimethyl fumarate 120 mg — 56
    dimethyl fumarate 120 mg (delayed release)56 per 28 days
    Alternative QLsAlso appears with 12 per 28 days and 120 per 180 days in other entries
    RequirementsPA; MO; QL noted
    inv-168: teriflunomide — 30
    teriflunomide30 per 30 days
    RequirementsPA; MO; QL per entry
    Therapeutic areaNeurology / MS agents
    inv-169: endocet example — 360
    endocet example360 per 30 days
    RequirementsQL (per entry)
    NotesOpioid/combination analgesic listing
    inv-170: fentanyl transdermal patch — 10
    fentanyl transdermal patch10 per 30 days
    RequirementsPA; MO; QL in some strengths
    Form72-hour transdermal patches (various mcg/hr)
    inv-171: hydrocodone-acetaminophen formulations — 5550
    hydrocodone-acetaminophen formulations5550 per 30 days (example entry)
    RequirementsMO; QL patterns vary by formulation
    NotesMultiple QL levels shown across opioid entries
    inv-172: methadone 5 mg — 240
    methadone 5 mg240 per 30 days
    RequirementsPA; MO; QL (per entry)
    ContextUsed in opioid therapy management listings
    inv-173: morphine oral solution — 900
    morphine oral solution900 per 30 days
    RequirementsMO; QL per formulary
    NotesConcentrates and solutions have large numeric QLs
    inv-174: ibuprofen example — 240
    ibuprofen examples240 per 30 days
    RequirementsMO; QL per entry
    FormOral suspension/tablet entries
    inv-175: lurbiro example — 2.4
    lurbiro example2.4 per 56 days
    RequirementsMO; QL recorded in table
    NotesUncommon numeric formats (decimal) appear in some QLs
    inv-176: naloxone injection solution — 3.2
    naloxone injection solution3.2 per 56 days
    RequirementsMO; QL per formulary entry
    UseNaloxone rescue therapy listing
    inv-177: aripiprazole tablet — 30
    aripiprazole oral tablet30 per 30 days
    RequirementsMO; QL per entry
    Therapeutic areaPsychiatric agents listing
    inv-178: ARISTADA INITIO — 4.8
    ARISTADA INITIO4.8 per 365 days
    RequirementsMO; QL (per entry)
    NotesLong-acting injectable with annual QL metric
    inv-179: ARISTADA (441 mg) — 1.6
    ARISTADA (441 mg)1.6 per 28 days
    RequirementsMO; QL noted
    ContextMultiple ARISTADA strengths with differing QLs
    inv-180: INVEGA SUSTENNA (various strengths) — 0.75-1.5 (per listing)
    INVEGA SUSTENNA (various strengths)0.75-1.5 per listing (examples: 0.75 per 28 days; 2.63 per 90 days; 1 per 28 days)
    RequirementsMO; QL; NDS across listings
    MappingEntries map to INVEGA TRINZA for longer-interval dosing
    inv-181: INVEGA SUSTENNA / TRINZA entries — e.g., QL (0.75 per 28 days); QL (2.63 per 90 days); QL (1 per 28 days)
    INVEGA SUSTENNA / TRINZA entriesExamples: QL (0.75 per 28 days); QL (2.63 per 90 days); QL (1 per 28 days)
    RequirementsMO; QL; NDS; some PA flags
    UseLong-acting injectable antipsychotics with dosing-interval QLs
    inv-182: sodium oxybate preferred NDCs starting with 00054 — QL (540 per 30 days) and alternate QL (60 per 30 days)
    sodium oxybate (preferred NDCs starting with 00054)QL (540 per 30 days) and alternate QL (60 per 30 days)
    RequirementsPA; MO; LA; QL; NDS depending on NDC grouping
    NotePreferred NDC grouping affects applicable QL
    inv-183: quetiapine formulations — QL (examples present)
    quetiapine formulationsQL values present (e.g., 90 per 30 days; 60 per 30 days; 120 per 30 days)
    RequirementsMO; QL per strength/formulation
    TieringTiers vary across formulations

    Site-of-Care Notes and Infusion Requirements

    Note
    Note
    Note
    Note

    Definitions and Abbreviations

    Background and Document Purpose

    This document is the CareSource MyCare Ohio formulary (the List of Covered Drugs) that sets out which drugs the plan covers and identifies utilization management controls (such as PA, QL, ST, and other requirement codes). It explains coverage conditions, how temporary supplies and transitions are handled, and provides contact information for members and providers to request exceptions or clarification.

    Biosimilar and Biological Product Substitution

    Note